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Abstract It has been recognized that cancer is not merely a
disease of tumor cells, but a disease of imbalance, in which
stromal cells and tumor microenvironment play crucial roles.
Extracellular matrix (ECM) as the most abundant component
in tumor microenvironment can regulate tumor cell behaviors
and tissue tension homeostasis. Collagen constitutes the scaf-
fold of tumor microenvironment and affects tumor microen-
vironment such that it regulates ECM remodeling by collagen
degradation and re-deposition, and promotes tumor infiltra-
tion, angiogenesis, invasion and migration. While collagen
was traditionally regarded as a passive barrier to resist tumor
cells, it is now evident that collagen is also actively involved
in promoting tumor progression. Collagen changes in tumor
microenvironment release biomechanical signals, which are
sensed by both tumor cells and stromal cells, trigger a cascade
of biological events. In this work, we discuss how collagen
can be a double-edged sword in tumor progression, both
inhibiting and promoting tumor progression at different stages
of cancer development.
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Introduction
Cancer is one of the most serious health threats worldwide,
with an estimated 12.7 million new cases and 7.6 million
cancer deaths each year [1]. Invasion and metastasis are the
most fundamental properties of tumor biology and the root
causes of cancer death. To tackle this problem, many efforts
focusing on tumor cells have been made over the past century,
and some genetic and epigenetic mechanisms have been elu-
cidated [2–6]. Currently, with a general consensus on the
significance of epigenetics, there has been a re-flowering of
theory that cancer is a disease of imbalance, i.e., not merely a
disease of rogue cells but the body's mismanagement of those
rogue cells. It has been well documented that tumor microen-
vironment plays an important role in tumor progression via the
co-evolution of tumor cells and tumor stroma [7–9]. Exploring
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the complex mechanisms of tumor progression from perspec-
tives of tumor stroma has become a new frontier.
Of note is the extracellular matrix (ECM), a major compo-
nent of tumor stroma, as a key regulator of cell and tissue
function. Traditionally, ECM has been regarded primarily as a
physical scaffold that binds cells and tissues together. How-
ever, recent studies have shown that ECM also elicits bio-
chemical and biophysical signaling [10, 11] that affects cell
adhesion and migration, tissue morphogenesis and repair,
angiogenesis and cancer, and ECM proteolysis is tightly con-
trolled in normal tissues but typically deregulated in cancer
[8]. As the most abundant constituent of ECM, collagen
accounts for the major function of ECM, and either increased
[12] or decreased [13] deposition of collagen can be associat-
ed with increased malignancy.
This review summarized the dynamic interplay between
collagen and tumor cells, focusing on changes in physico-
chemico-biological properties of collagen. A new paradigm
has been formulated that the intrinsic biomechanical forces in
collagen can modulate ECM molecular conformation, produc-
ing either protective or destructivemolecular and cellular events
during tumor progression, depending on the stage of cancer
development. Furthermore, the relationship between collagen
and immune response and tumor angiogenesis is also explored.
Basic structure and function of collagen
Collagen is abundant in humans accounting for one-third of
total proteins. The fibrous, structural protein contains three
polypeptide α-chains, displaying a polyproline-II conforma-
tion, a right-handed supercoil and a one-residue stagger be-
tween adjacent chains [14]. Each polypeptide chain has a
repeating Gly–X–Y triplet, and the three polypeptide α-
chains in the triple helix held together by inter-chain hydrogen
bonds can be identical, but heterotrimeric triple helices are
more prevalent than homotrimeric triple helices. Gauba and
Hartgerink [15] observed that assembly of heterotrimeric tri-
ple helices was based on the 1:1:1 mixture of (ProLysGly)10/
(AspHypGly)10/(ProHypGly)10 (Fig. 1). Collagen undergoes
extensive posttranslational modifications by hydroxylation
and cross-linking reactions in the endoplasmic reticulum prior
to triple helix formation [16]. A number of enzymes and
molecular chaperones assist in their correct folding and
trimerisation, including hydroxylases, collagen glycosyltrans-
ferases, peptidyl cis–trans isomerase and protein disulphide
isomerase [17, 18]. According to the structure properties of
ECM, collagens can be categorized into classical fibrillar and
network-forming collagen, FACITs (fibril-associated
collagens with interrupted triple helices), MACITs
(membrane-associated collagens with interrupted triple
helices), and MULTIPLEXINs (multiple triple-helix domains
and interruptions) [19]. At least 28 different types of collagens
have been identified in vertebrates [19, 20] (Table 1). Among
these, type I collagen is the archetypal collagen in that its triple
helix has no imperfections and it has predominant role in
tissue [16]. Others can have interruptions in the triple helix
and do not necessarily assemble (in their own right) into
fibrils. For example, MACIT has numerous interruptions in
the triple helix, does not self-assemble into fibrils, and has
roles in cell adhesion and signaling [20]. And Type IV colla-
gen is the prototypical network-forming collagen. It forms an
interlaced network at basement membrane (BM), found at the
basal surface of epithelial and endothelial cells and essential
for tissue polarity [21], where it has an important molecular
filtration function.
ECM remodeling during cancer invasion
During cancer invasion, tumor stroma undergoes constant
architectural changes, characterized by collagens degrading,
re-depositing, cross-linking and stiffening in terms of ECM
remodeling, and immune infiltration and re-differentiation of
monocytes at the invasive front in terms of cellular changes.
Increased deposition and cross-linking of collagens
The ECM scaffold undergoes considerable structural changes
during tumor progression, including increased deposition of
fibronectin, proteoglycans and collagens I, III and IV, and
enhanced matrix cross-linking [22, 23]. Increased ECM de-
position and remodeling creates a reorganized microenviron-
ment to promote tumor progression by destabilizing cell po-
larity and cell–cell adhesion, and augmenting growth factor
signaling [10, 24]. The progressive ECM remodeling pro-
duces typical morphological changes characterized by linear-
ization of interstitial collagens at tumor invasion front, with
significant impacts on tumor cell biology including gene
expression, cell differentiation, proliferation, migration and
responses to treatments [10].
Breast cancer is a typical example of these changes. Clini-
cians have long recognized the connection between breast
density and breast cancer risk [25]. Collagen surrounding
normal epithelial structures in breast tissue is typically curly
and smooth. However, parallel with tumor development, col-
lagen progressively thickens, linearizes and stiffens which
promotes metastasis by fostering cells migration into ECM.
Indeed, intravital imaging shows that breast cancer cells and
leukocytes migrate rapidly along collagen fibers [26]. Cancer
cells might exploit these remodeled stiff collagens as invasion
"highways", analogous to the preferential migration of glioma
cells along the matrix associated with blood vessels and rigid
myelin sheath bundles [27]. Our recent study also observed
the linear invasion "highways" in hepatocelluar carcinoma
(HCC) (Fig. 2).
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Fig. 1 Biosynthesis of collagen. Three polypeptide α-chains each in-
cluding an N- and C-terminal propeptides form triple helical structures
called procollagen triple helix by lysly hydroxylase, protein disulfide
isomerase and hydrogen bonds. Neutral strands are stable, but charged
forms are unstable. Tropocollagen triple helix is formed as N- and C-
terminal propeptides are converted into N- and C-terminal peptides by N-
and C-proteinases. Under lysyl oxidase (LOX) cross-linking and self-
assembly, collagen fibers or networks are formed
Table 1 Collagens in vertebrates
at a glance
BM basement membrane, FACIT
fibril-associated collagens with
interrupted triple helices, MACIT
membrane-associated collagens
with interrupted triple helices,
MULTIPLEXINs multiple triple-
helix domains and interruptions
Type Class Distribution
I Fibril Abundant and widespread in non-cartilaginous connective tissue:
dermis, bone, tendon, ligament
II Fibril Cartilage, vitreous
III Fibril Co-distribution with collagen I: skin, blood vessels, intestine
IV Network BM
V Fibril Widespread and co-distribution with collagen I: bone, dermis, cornea, placenta
VI Network Widespread: muscle, bone, cartilage, cornea, dermis
VII FACIT Dermis, bladder
VIII Network Widespread: dermis, brain, heart, kidney
IX FACIT Co-distribution with collagen II: cartilage, cornea, vitreous
X Network Hypertrophic cartilage
XI Fibril Co-distribution with collagen II: cartilage, intervertebral disc
XII FACIT Co-distribution with collagen I: dermis, tendon
XIII MACIT Endothelial cells, dermis, eye, heart
XIV FACIT Widespread and co-distribution with collagen I: bone, dermis, cartilage
XV MULTIPLEXIN Located between collagen fibrils that are close to BM, capillaries, testis,
kidney, heart
XVI FACIT Integrated into collagen fibrils and fibrillin-1 microfibrils, dermis, kidney
XVII MACIT Hemidesmosomes in epithelia
XVIII MULTIPLEXIN Associated with BM, liver
XIX FACIT Rare, localized to BM
XX FACIT Widespread: cornea (chick)
XXI FACIT Widespread: stomach, kidney
XXII FACIT Tissue junctions
XXIII MACIT Limited distribution: heart, retina
XXIV Fibril Shares sequence homology with the fibril-forming collagens: bone, cornea
XXV MACIT Brain, heart and testis
XXVI FACIT Testis and ovary
XXVII Fibril Shares sequence homology with the fibril-forming collagens: cartilage
XXVIII Network A component of the BM around Schwann cells, dermis, sciatic nerve
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Protease-dependent collagen cross-linking based on LOX
Protease dependent-ECM remodeling is predominantly cata-
lyzed by enzymes such as lysyl oxidase (LOX) [28], synthe-
sized by either stromal cells during early stages of carcino-
genesis, or tumor cells during late stages of tumor progression
in response to hypoxia [29]. As shown in Fig. 3, LOX,
secreted by prominent central hypoxic tumor cells, can
crosslink collagens and elastin, thereby increasing insoluble
matrix deposition and tissue stiffness (Table 2). Increased
ECM stiffness can activate integrins [30], enhance tumor cell
adhesion and migration [31–33]. LOX is essential in driving
tumor cells escape from primary site, extravasation and
growth at secondary sites during metastasis [29, 34]. It is
reported that LOX can be disseminated into distal target
organs via circulation to mobilize bone marrow derived cells
(BMDCs) to distal sites, and to create pre-metastatic niche
[29], as evidenced by consistent correlation between increased
LOX expression and higher cancer metastasis risk [34]. Fur-
thermore, increased LOX expression is associated with early
stromal reaction in breast cancer, and reactive fibrosis at the
invasive front of infiltrating tumors also releases high levels of
LOX [33]. The secreted LOX acts on collagen and increases
integrin activity, stimulating tumor cells to stretch pseudopo-
dia protrusions with increased actin polymerization, focal
adhesion formation, resulting in the enhancement of
actomyosin- and cytomyosin-dependent cell contractility and
migration, leaving behind remodeled matrix tracks as the
"metastasis highway" for tumor cells to travel. In more ag-
gressive and poorly differentiated tumors, LOX also induces
epithelial–mesenchymal transition (EMT) and promotes met-
astatic dissemination by facilitating tumor cells invasion into
vascular system (intravasation) [35].
Protease-independent ECM stiffening
Non-enzymatic collagen cross-linking, such as glycation and
transglutamination or increased biglycan and fibro-modulin
proteoglycan deposition, can also stiffen matrix [36]. Such
protease-independent ECM stiffening could be divided into
several models. One kind is the excessive deposition of pro-
teoglycans. It could contribute to fibrosis by parenchyma stiff-
ening in injured lungs [37], and be accompanied with elevated
risk of developing cancers in diabetic patients with inappropri-
ate glycation-mediated cross-linking [38–40]. Another process
is fibronectin-mediated collagen reorganization [48]. The size,
density and rigidity of fibronectin in vivo influence function of
collagen, and dynamic and reciprocal interactions between
collagen and fibronectin likely induce tumor progression
[41]. Indeed, fibronectin has been implicated as early step of
cancer metastasis [42]. And secreted protein acidic and rich in
cystine (SPARC), a highly conserved, multi-functional glyco-
protein, produced both by cancer cells and stromal cells, can
also be involved with such protease-independent ECM stiffen-
ing models. It could participate in ECM organization and bind
to type I and IV collagen [13] and also suppress or promote
progression of cancers depending on interactions at cell-matrix
and tumor-stroma surface [13, 43–46].
Increased degradation of collagen
Collagen in tissues has been traditionally regarded as merely a
physical barrier against cancer invasion and tumor cells mi-
gration [47, 48]. The prerequisite for tumor invasion is colla-
gen degradation [49], for which matrix metalloproteinases
(MMPs) play an important role [8, 50], with direct causative
effects on tumor growth, invasion and angiogenesis [51–63],
Fig. 2 Type IV collagen
expression demonstrated by
quantum dot-525 (green). a
Abundant type IV collagen
fragments stochastically
distributed in tumor tissues. b
Rich type IV collagen in tumour
stroma aligning with tumor nests.
c , d Different characteristics
between HCC (red star) and live
cirrhosis (LC) tissues. Red
arrowheads show stiff type IV
collagen at interface of liver
cirrhosis and tumor nests. Red
arrows indicate the linear
invasion "highways" for tumor
cells escape. Scale bar=50 μm
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by a host of mechanobiological mechanisms such as to de-
grade collagen paving a potential tunnel for escaping tumor
cells [8], to disturb tumor microenvironment producing addi-
tional mechanical force to induce EMT, and to expose active
sites on collagen to recruit monocytes leading to a cascade of
innate immuno-inflammatory reactions [54]. However, there
is diversity of tumor invasion mechanisms, in which collagen
degradation plays different roles. In single cell/amoeboid mi-
gration, cells tend to migrate in the absence of proteolytic
ECM breakdown by adapting their shape to and squeezing
Fig. 3 The role of LOX in tumor progression both in situ and distal
organs. With tumor growth beyond 2 mm in diameter, prominent central
hypoxia induces tumor cells to secrete LOX into tumormilieu. On the one
hand, LOX-mediated type IV collagen cross-linking leads to ECM depo-
sition and subsequent tissue stiffness, driving malignant progression
predominantly by altering integrin focal adhesions and actomyosin- and
cytoskeletal-dependent cell contractility. Tumor cells stretch pseudopodia
protrusions with increased actin polymerization, focal adhesion formation
and focal adhesion kinase that can in turn enhance tumor cells prolifera-
tion, migration, invasion, and perhaps tumor angiogenesis. On the other
hand, LOX is disseminated into target organs (lung in this illustration) via
circulation and deposits at terminal bronchioles and distal alveoli. The
deposited LOX can crosslink type I and IV collagens to remodel ECM for
recruiting BMDCs, so as to form the pre-metastatic niche
Table 2 Up-regulated expression of LOX in tumor tissues
Cancer type Results Function References
Breast cancer 10-year DMSFa low
10-year OSb low
Activate HIF1-Akt pathway; mediate hypoxic control of metastasis; regulate
actin filament formation; contribute to mechanotransduction-mediated
regulation of TGF-β signaling; recruit BMDCs to form the pre-metastatic niche
[29, 34, 36]
Colorectal cancer / Correlated with absence of lymphovascular invasion; activate PI3K–Akt
pathway to up-regulate HIF-1α protein synthesis
[37, 38]
Head and neck squamous
cell carcinoma
5-year OSc low Strongly associated with increased metastasis, progression and death [39]
Lung adenocarcinoma 5-year OS low ECM remodeling; associated with advanced stage and metastasis [40, 41]
Oral and oropharyngeal
squamous cell carcinoma
10-year OS low Independent prognostic biomarker and predictor of lymph node metastasis [42]
a 10-year DMSF: 10-year distant metastasis free survival
b 10-year OS low: 10-year overall survival
c 5-year OS low: 5-year overall survival
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through tissue gaps and trails. In mesenchymal migration,
invading cells adopt spindle-shaped, elongated morphology
with focalized cell-matrix adhesions containing multi-
molecular integrin clusters and proteolytic activity toward
ECM substrates. Focalized proteases on the cell's surface
generate small microtracks through which subsequent cells
can follow. In collective invasion, one or several leader cells
with mesenchymal characteristics, such as fibroblasts, form
the tip of multi-cellular strands and generate forward traction
and pericellular proteolysis toward the tissue structure [49].
Recent studies have gained new insights into the function
of MMPs with a new paradigm for mechanobiological mech-
anisms in tumor invasion [55], which will be described in
detail below.
Reversible changes of BM: opening the door
for non-proteolytic ECM migration
At initial phase of tumor invasion, BM is breached as tumor
cells invade into interstitial tissue and colonize distant organs.
Although proteolysis-dependent collagen degradation is im-
portant for this process, there is much evidence showing that
proteolysis is dispensable in the BM transmigration events
[56, 57].
In this process, the putative mechanism underlying revers-
ible BM remodeling could rely on a precedent wherein endo-
thelial cells function as the gatekeeper of transmigration by
flexibility on BM [58]. That is, endothelial cells can generate
traction force in response to signals during tumor cell–endo-
thelial cell adhesive interactions, which regulate collagen
structure and organization. Indeed, BM has been proposed to
display thixotropic properties: an increasing force generates a
change in BM viscosity, altering BM permeability to macro-
molecules and perhaps even cells [59]. So, in such a scenario,
reversible disruptions of type IV collagen quaternary interac-
tions are required for "closing and opening" BM, permitting
non-proteolytic transmigration to occur without enzymatic
degradation [60]. In this manner, a reversible system might
be envisioned wherein tumor cells or others such as mono-
cytes can be accommodated to pass through. Thus, collagen
can regulate immune cell infiltration into tumors. Hence,
cooperation between traction forces and the activity of cell
surface enzymes on either the endothelial cell or tumor cells
themselves theoretically would enable the reversible opening
and closing of BM [61, 62].
Thus, collagen increase and decrease are both involved in
tumor progression, and these two processes are coordinated
reciprocally to promote tumor invasion and metastasis. First,
LOX mediated collagen cross-linking can recruit some stro-
mal cells to adhere and secrete moreMMPs. Then, MMPs can
degrade collagen to expose active sites to generating a pro-
tumorigenic microenvironment to facilitate tumor progres-
sion. Although direct mechanisms have not been elucidated,
MMPs are associated with LOX expression in breast cancer
[29]. LOX mediated collagen cross-linking seems to function
in synergy with MMPs, which may lead to ECM remodeling
favoring tumor progression.
Tension homeostasis and tumor progression
Force is essential for normal tissue-specific development, in
which it regulates cell survival, growth and migration, and
orchestrates tissue organization and function. Increased matrix
cross-linking and ECM protein deposition or parallel reorien-
tation of matrix collagen can stiffen tissue locally to alter
surrounding cells growth or drive cell migration. Loss of
tissue homeostasis and mechanoreciprocity is a hallmark of
disease. Although much is known about biochemical path-
ways that direct cell behavior, by comparison, little is known
about how force regulates cell fate and tissue phenotype. Two
primary cellular mechanisms involved in tumor invasion and
migration are cellular physical rearrangement and reorienta-
tion of collagen by traction forces generated by epithelial cells
[63, 64], the consequence of EMT and cellular catabolism of
ECM by enzymatic cleavage of collagen [65–67]. Both can be
regulated by tissue tension. Here we take a multiscale ap-
proach to describe tension homeostasis changes present at
tumor–stroma interface, ranging from the molecular level
(collagen and specific enzymes secreted by tumor and stromal
cells involved in collagen reorganization) and the cellular
level (tumor and stromal cells) to the structural level (ECM)
[65, 68, 69].
EMT process
Interactions between tumor cells and their surrounding ECM
are recognized as primary forces driving the EMT process
[68]. Imbalanced biomechanical force at tumor–stroma inter-
face is the key trigger initiating EMT, and ultimately leads to
tumor cells escaping [55]. Tumor cells dynamically adapt to
the force (Fig. 4) by changing their behaviors and remodeling
their surrounding microenvironment. As the tumor mass ex-
pands at early stages of the invasion, collagen in stroma will
realign and stretch perpendicular to the mass to resist tumor
expansion and enzymatic degradation. Thus, tumor cells must
overcome increased collagen alignment and density before
invasion and migration. With the tumor mass expanding,
stress on ECM increases correspondingly, until reaching a
critical point, termed as the biomechanical trigger [62], which
can be sensed by both tumor and stromal cells through mech-
anoreceptors. In turn these cells exert actomyocin- and
cytoskeletal-dependent traction forces on ECM [70–72].
Eventually, tumor and stromal cells deform as consequences
to the altered tissue tension [73, 74], the expanding tumor
mass [24], matrix stiffening [10], and increased interstitial
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pressure due to a leaky vasculature and poor lymphatic drain-
age, initiating EMT [75]. These deformed cells acquire a more
spindle-like fibroblastic morphology, less adhesive properties,
enhanced motility and invasive behavior.
Tension as a regulator for MMPs function
ECM degradation is necessary for tumor invasion. However,
collagen as one of the most abundant components of ECM is
the largest, strongest and most difficult to penetrate by tumor
cells due to limited degradation by only a few MMPs. And
also collagen undergoes remodeling and reorientation in re-
sponse to tumor mass expansion, with a concomitant increase
in collagen density and mechanical tension to constrain tumor
expansion [70, 76]. Re-constructed collagen can prevent them
from being degraded by MMPs. As shown in Fig. 5, in normal
tissues,MMPs can access into collagen to degrade (Fig. 5a1–a2).
However, in tumor tissues, function ofMMPs is regulated by the
tumor microenvironment, here accenting the coordination of
stromal cells, tumor cells and collagen as well: (1) initially,
increased tension in ECM is protective, it makes the collagen
stretched, in that it inhibits MMP-related collagen cleavage as
collagen undergoes molecular conformation changes, such that
the enzymes no longer have access to the cleavage site on
collagen as the binding sites hidden (Fig. 5b1–b2); (2) with the
tumor extensively expansion, tumor cells and stromal cells sense
high tension in ECM so as to exert traction force on collagens to
make them deform through integrin binding (Fig. 5c1–c2); (3) as
tension exerting on cells increases with further tumor mass
expansion until a critical point, rather than being protective for
ECM degradation, increasing tension becomes a key biome-
chanical trigger for tumor and stroma cells to remodel the
ECM. Via surface integrin receptors, cancer cells can sense
mechanical signals of increasing tension in the microenviron-
ment, and respond by increasing their traction forces on ECM,
resulting in collagen triple helix separation (Fig. 5d1–d2); (4)
thus, entrance hole for MMPs is opened by destabilizing
collagen triple helix and unwinding collagen molecule
(single α-chain) [62], accompanied with tension decrease in
ECM (Fig. 5e1–e2).
Thus, during tumor progression, ECM remodeling contrib-
uting to tension changes is important for both triggering EMT
and regulating MMPs. As the tumor expands, the tension in
ECM will increase correspondingly, until reaching a critical
point [55]. This may be a turning point for most tumors and
before reaching this turning point, tumor progresses slowly,
but beyond this turning point, tumor progression is
accelerated.
Collagen as a regulator for tumor associated immune
infiltration
Collagen is not just a passive player during tumor progression.
Recent experimental developments point to a far more com-
plex role for these structure proteins. A variety of immune
cells are present in cancers and many of these accumulate and
migrate within regions of dense collagen [26, 77, 78].
For example, macrophages in and around tumor nests can,
in principle, either promote or inhibit tumor progression [79],
Fig. 4 Force applied to deform
and influence the biological
behavior of tumor cells. Tissue
microenvironment can exert
three forms of force on tumor
cells, including shear stress,
compressive stress and
tensile stress
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and collagen plays a crucial role in regulating the balance
between the tumor-inhibiting and promoting effects of mac-
rophages. It is reported that culturing macrophages on type I
collagen reduces their cytotoxicity against tumor cells [80],
suggesting that collagen inhibits the differentiation of the
macrophages to the tumoricidal M1-like type. The possibility
that collagen scaffolds can regulate macrophages polarization
is further supported by the increase in pro-tumorigenic, M2-
like macrophages observed in tumors of Sparc−/− mice with
abnormal collagen scaffolds [13]. The principal factors behind
this transformation appear to be interleukin-6 (IL-6) and
colony-stimulating factor 1 (CSF-1) [81]. And it is also known
that collagen degradation products serve as chemotactic stim-
uli for monocytes [82, 83]. As collagen is degraded during
metastasis, the resulting collagen fragments may recruit tumor
associated macrophages (TAMs). These TAMs are abundant
in most solid tumors [84], predicting poor prognosis [85]. As
shown in Fig. 6, monocytes are recruited into collagens deg-
radation areas accompanied with MMPs release by tumor
cells [85]. After releasing soluble CSF-1, monocytes differen-
tiate into TAMs promoting tumor growth and metastasis [85].
Similarly, IL-6 will inhibit monocytes differentiation into
dendritic cells, directing immune responses against tumor
cells [85]. TAMs themselves express factors in response to
tumor progression, promoting tumor angiogenesis, invasion
and intra-and extravasation [86, 87]. For example, IL-1β, a
special form of IL-1, can stimulate expression of VEGF and
TNFα to promote tumor angiogenesis and adhesion mole-
cules, including intercellular-adhesion molecule 1 (ICAM-1),
vascular cell adhesion molecule 1 (VCAM-1) and E-selectin,
to enhance invasion. And IL-1β can also activate MMPs to
degrade collagen [88, 89]. Thus, all these have uncovered a
significant positive feedback in immune responses to cancer-
related collagen degradation and indicate the link between
degraded type IV collagen and tumor progression [90].
In addition, ECM stiffness could influence T cell activation
via integrin-mediated adhesions assembly promotion [10, 90]
and collagen-mediated activation of leukocyte-associated Ig-
like receptors (LAIRs). LAIRs are highly expressed on most
immune cells and can through their immunoreceptor tyrosine-
based inhibition motifs (ITIMs) inhibit immune cell activation
[91]. Although it is not clear whether LAIRs and integrins
Fig. 5 A paradigm for how tumor and stromal cells interact to degrade
ECM and change tensions for tumor invasion. a1 Dormant tumor cells
without tension force; a2 collagen relaxed and elastic. b1 With tumor
growth, low tension force exerts on collagen which stretches accordingly;
b2 Entrance hole for MMPs-dependent cleavage is closed as collagen
stretches. c1 As the tumor continues to expand, increasing tension force
transmits signals to both tumor and stromal cells to remodel ECM in order
to reduce tension force. Tumor and stromal cells undergo EMT process
which in turn increase their traction force; c2 collagen bends and changes
conformational structures correspondingly. d1 High traction force
exerted by cells destabilize the stroma; d2 tumor and stromal cells attach
to collagen and unwind triple helix, exposing sites for cleavage by
MMPs. e1 Tumor invasion and metastasis occur with degradation of
collagen; e2 MMPs enter into triple helix to cleave α-chains
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cooperate, activation of LAIRs is a plausible mechanism
whereby high levels of deposited collagen lead to inhibition
of an anti-tumor immune response.
As collagen influences immune cell infiltration, immune
cells also influence collagen architecture. Macrophages regu-
late mammary epithelial invasion during tissue development
[92]. This may in part be achieved through their ability to
initiate the remodeling and reorganization of collagen sur-
rounding the developing epithelium [93], and secretion of a
repertoire of soluble factors such as MMPs. Macrophages can
also take up collagen for intracellular degradation via binding
to the glycoprotein [94, 95].
Collagen and tumor angiogenesis
Angiogenesis, a specialized form of branching morphogenesis
wherein endothelial cells detach themselves from the existing
vasculature, invade surrounding tissues, and reorganize into
patent tubules [86, 96], is vital for tumor growth and metasta-
sis. Tumor angiogenesis is characterized by the secretion of
multiple pro-angiogenic factors to trigger the angiogenic
switch resulting in the development of a structurally and
functionally abnormal vasculature.
Collagens are essential for tumor angiogenesis. Inhibition
of collagen metabolism has been demonstrated to have anti-
angiogenic effects [97], confirming that blood vessel forma-
tion and survival are indispensably connected with proper
collagen synthesis and deposition at BM [97]. Interactions
between endothelial cells and ECM, in particular collagen
IV in the vascular basement membrane (VBM) play key roles
in regulating angiogenesis [21]. For instance, type IV collagen
could modulate (promote/inhibit) endothelial cells growth and
proliferation [98]. The in vitro endothelial cells culture exper-
iments have shown that triple-helical fragments of type IV
collagen could stimulate endothelial-cell adhesion and migra-
tion as active as intact type IV collagen, while the
noncollagenous domain 1 (NC1 domain) of type IV collagen
alone is insufficient to mediate endothelial-cell migration [99,
100]. And a further research of NC1 domains indicated that
they are typical anti-angiogenic molecules, which could in-
hibit endothelial cells migration, proliferation and tube forma-
tion by competing with intact type IV collagen for binding
integrin [101]. In addition, studies on in situ carcinoma dem-
onstrated that MMP-mediated degradation of BM could ex-
pose cryptic domains of type IV collagen with pro-angiogenic
activity, in the early stage of local tumor progression [102,
103], and generate type IV collagen fragments with anti-
angiogenic activity, such as arrestin, canstatin and tumstatin
in the late stage [104–106]. Thus the structural integrity of
collagen IV is of utmost importance for tumor angiogenesis
[21].
Conclusions and future perspectives
Over the last 10 years, cancer research has been increasingly
shifted to the tumor microenvironment. In particular, ECM,
the intermediary between biomechanics and tumor biology,
can mediate dual roles as tumor suppressors at the early stages
Fig. 6 Collagen regulates tumor associated immune infiltration. MMP-
dependent collagen fragments can recruit monocytes and further promote
them to differentiate into TAMs with the help of CSF-1. TAMs
themselves secret factors responsible for tumor progression, including
tumor angiogenesis. Meanwhile, they themselves can activate MMPs to
degrade collagens
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but paradoxically as tumor promoters at the later stages of
tumor progression. Current researches of ECM focus on bio-
chemical mechanisms associated with tumor progression,
namely the intracellular pathways of signal transduction from
the ECM to the nucleus (outside-in signaling), and the cellular
metabolic responses for synthesizing proteinases to degrade
(inside-out signaling) [62]. However, little attention has been
paid to the dynamic changes of ECM biomechanics accom-
panying these biochemical events. With the increasing appre-
ciation that biomechanical forces are crucial determinants for
tissue development, cell differentiation and homeostasis, it is
reasonable to conclude that loss of the ability to sense, respond
and adapt appropriately to such biomechanical forces, on the
part of tumor cells and stromal cells, contributes to tumor
progression. Therefore, collagen as the most important archi-
tecture of ECM to generate these biomechanical forces, is no
longer considered as a static and passive background upon
which metastasis takes place. To elucidate how the changes in
collagen structure and the related biomechanical forces to
modulate tumor invasion and metastasis, thus deciphering
the "collagen code" in cancer progression, is an intriguing
field for intensive investigation.
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